Clinical Trial

Imaging Immune Activation in COVID-19

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-03-23; most recent amendment 2026-05-05.
Status change: Enrolling by Invitation → Recruiting 2021-03-24
Trial Details
NCT Number NCT04815096
Lead Sponsor CellSight Technologies, Inc.
Collaborators: University of California, San Francisco
Conditions Covid19, SARS-CoV Infection
Enrollment 80 participants
Start Date 2021-04-15
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08